South Korea's Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products, enacted in 2019, was recently amended. This article examines the new advanced regenerative medicine treatment (ARMT) category, focusing on patient access, review processes, safety monitoring, ethical safeguards, and lessons from Japan's comparable framework.
Yoon et al. (Sun,) studied this question.